Get the Stockscreener App
0.00
100.00%
-17.03
After Hours:
17.04
17.04
+
Theravance Biopharma Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
See More
Previous Close:
$17.03
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$884.18M
Revenue:
$109.78M
Net Income/Loss:
$114.54M
P/E Ratio:
0.00
EPS:
2.2046
Net Cash Flow:
$268.74M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$17.08
52-Week Range:
$0.00
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
0.00 | 884.18M | 109.78M | 114.54M | 268.74M | 2.2046 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-04-26 | Downgrade | B. Riley Securities | Buy → Neutral |
| Dec-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-12-25 | Initiated | B. Riley Securities | Buy |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Theravance Biopharma (TBPH) shares were canceled on September 23 after its Zymeworks merger. - Stock Titan
Theravance Biopharma Insider Brett Grimaud Reports Complete Share Cancellation Following Zymeworks Merger - Kalkine Media
Form 4 Theravance Biopharma For: 24 September By Investing.com - Investing.com Canada
Zymeworks now owns Theravance Biopharma (TBPH). A director's shares were canceled for cash and milestone rights. - Stock Titan
A director's shares became rights to $17 each plus a contingent payment in Theravance Biopharma's (TBPH) merger. - Stock Titan
A 150,000-share insider option was cancelled without payment in Theravance Biopharma (TBPH)'s merger. - Stock Titan
Vancouver biotech Zymeworks closes US$929M Theravance deal - biv.com
Zymeworks Completes Acquisition of Theravance Biopharma - Indovizka.com
TBPH Suspended by BTIGAnalyst Rating Remains Neutral - GuruFocus
Zymeworks Finalizes Merger with Theravance Biopharma and Launches $350M Senior Secured Notes - Kalkine Media
Precision Trading with Theravance Biopharma Inc. (TBPH) Risk Zones - Stock Traders Daily
Zymeworks completes acquisition of Theravance Biopharma By Investing.com - Investing.com Australia
Theravance Biopharma CEO Rick E Winningham resigns; Kristin Stafford, Scott Platshon and Paul Schneider named directors - TradingView
Theravance Biopharma (Nasdaq: TBPH) is named in a notice to remove its shares from Nasdaq. - Stock Titan
Zymeworks completes acquisition of Theravance Biopharma - Investing.com
Theravance Biopharma, Inc. Announces Resignation of Rick E Winningham from Chief Executive Officer, Effective September 23, 2026 - marketscreener.com
A $350 million debt issue helped fund Zymeworks (ZYME)'s Theravance acquisition, with cash due per eligible share. - Stock Titan
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from NASDAQ Biotechnology Index - marketscreener.com
Theravance Biopharma issues disclosures amid Zymeworks merger - TipRanks
Form 8K Theravance Biopharma Inc For: 18 September By Investing.com - Investing.com Nigeria
Theravance Biopharma Shareholders Endorse Merger with Zymeworks Inc. - Kalkine Media
Theravance Biopharma shareholders approve merger with Zymeworks - Investing.com
Theravance Biopharma shareholders approve merger with Zymeworks By Investing.com - Investing.com Nigeria
Theravance Biopharma SVP Farnum Rhonda Sells 13,314 Shares at $17.03 Each - Kalkine Media
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Navigating the Biotech Seas with Strategic Collaborations - DirectorsTalk Interviews
Theravance Biopharma (TBPH) Insider Sale: SVP, COMM & MEDICAL AF - GuruFocus
Theravance Biopharma SVP Rhonda Farnum sells $226k in stock - Investing.com India
Theravance Biopharma SVP Rhonda Farnum sells $226k in stock By Investing.com - Investing.com South Africa
Pre-arranged stock sale at Theravance Biopharma (TBPH) - Stock Titan
Theravance Biopharma (NASDAQ: TBPH) officer plans $226,793 stock sale - Stock Titan
Price-Driven Insight from (TBPH) for Rule-Based Strategy - Stock Traders Daily
Theravance Biopharma Inc (NASDAQ: TBPH) Share Price, TBPH Stock News, TBPH Share Price & Updates - kalkine.com.au
Form 8K Theravance Biopharma Inc For: 10 September By Investing.com - Investing.com South Africa
Theravance Bi in merger with Zymeworks faces shareholder suits, supplements proxy with disclosures - TradingView
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Theravance Biopharma Inc. (TBPH) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Theravance Biopharma Inc. (TBPH) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
How (TBPH) Movements Inform Risk Allocation Models - Stock Traders Daily
Theravance Biopharma reports CYPRESS Phase 3 miss but FDA grants Type C meeting to discuss future trial - TradingView
Theravance Biopharma (NASDAQ:TBPH): What Could Its Scheduled Update Reveal? - Kalkine Media
FDA says Theravance (TBPH) needs more data on nOH drug trial - Stock Titan
Theravance (TBPH) Q1 2026 Scorecard: EPS Beats Its Estimate in the Current Update; Closing Move: The Stock Records a Flat ReactionForward EPS Estimate - vinanet.vn
Theravance (NASDAQ: TBPH) sets vote on cash buyout with ampreloxetine CVR upside - Stock Titan
Madison Avenue Partners, LP Trims Theravance Biopharma Inc (TBPH) Stake in Portfolio Rebalancing Move - GuruFocus
Theravance Biopharma, Inc. Revenue Breakdown – NASDAQ:TBPH - TradingView
Theravance (TBPH) Update: Rises 0.18% to $16.98 on the Day; Price Setup: Traders Can Monitor the $16.13-$17.83 RangeSupport Level Bounce - vinanet.vn
Theravance Biopharma (TBPH) Edges Higher to $16.97, Trapped Between Key Support and ResistanceFactor Valuation - vinanet.vn
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):